Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials

被引:9
作者
Sridhar, Vikas S. [1 ,2 ,3 ,4 ]
Ambinathan, Jaya Prakash N. [1 ,2 ,3 ,4 ]
Gillard, Pieter [5 ]
Mathieu, Chantal [5 ]
Cherney, David Z., I [1 ,2 ]
Lytvyn, Yuliya [1 ]
Singh, Sunita K. [1 ,2 ,3 ,4 ]
机构
[1] Toronto Gen Hosp, Univ Hlth Network, Div Nephrol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Toronto Gen Hosp, Univ Hlth Network, Kidney Transplant Program, Toronto, ON, Canada
[4] Toronto Gen Hosp, Univ Hlth Network, Airrera Tranplant Ctr, Toronto, ON, Canada
[5] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Endocrinol, Leuven, Belgium
基金
加拿大健康研究院;
关键词
LONG-TERM OUTCOMES; NEUTRAL ENDOPEPTIDASE INHIBITION; PEPTIDE-1 RECEPTOR AGONISTS; COTRANSPORTER; INHIBITORS; POST-HOC ANALYSIS; CARDIOVASCULAR OUTCOMES; DOUBLE-BLIND; PRACTICE GUIDELINE; SGLT2; ACUTE REJECTION;
D O I
10.1097/TP.0000000000003919
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Kidney transplantation is the therapy of choice for patients with end-stage renal disease. Preexisting diabetes is highly prevalent in kidney transplant recipients (KTR), and the development of posttransplant diabetes is common because of a number of transplant-specific risk factors such as the use of diabetogenic immunosuppressive medications and posttransplant weight gain. The presence of pretransplant and posttransplant diabetes in KTR significantly and variably affect the risk of graft failure, cardiovascular disease (CVD), and death. Among the many available therapies for diabetes, there are little data to determine the glucose-lowering agent(s) of choice in KTR. Furthermore, despite the high burden of graft loss and CVD among KTR with diabetes, evidence for strategies offering cardiovascular and kidney protection is lacking. Recent accumulating evidence convincingly shows glucose-independent cardiorenal protective effects in non-KTR with glucose-lowering agents, such as sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Therefore, our aim was to review cardiorenal protective strategies, including the evidence, mechanisms, and rationale for the use of these glucose-lowering agents in KTR with diabetes.
引用
收藏
页码:734 / 748
页数:15
相关论文
共 201 条
  • [71] How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    Fitchett, David
    Wanner, Christoph
    Ferrannini, Ele
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Johansen, Odd Erik
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    [J]. DIABETES CARE, 2018, 41 (02) : 356 - 363
  • [72] Predicting Coronary Heart Disease after Kidney Transplantation: Patient Outcomes in Renal Transplantation (PORT) Study
    Israni, A. K.
    Snyder, J. J.
    Skeans, M. A.
    Peng, Y.
    Maclean, J. R.
    Weinhandl, E. D.
    Kasiske, B. L.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (02) : 338 - 353
  • [73] The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
    Jardine, Meg J.
    Mahaffey, Kenneth W.
    Neal, Bruce
    Agarwal, Rajiv
    Bakris, George L.
    Brenner, Barry M.
    Bull, Scott
    Cannon, Christopher P.
    Charytan, David M.
    de Zeeuw, Dick
    Edwards, Robert
    Greene, Tom
    Heerspink, Hiddo J. L.
    Levin, Adeera
    Pollock, Carol
    Wheeler, David C.
    Xie, John
    Zhang, Hong
    Zinman, Bernard
    Desai, Mehul
    Perkovic, Vlado
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2017, 46 (06) : 462 - 472
  • [74] Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients
    Karpe, Krishna M.
    Talaulikar, Girish S.
    Walters, Giles D.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (07):
  • [75] The burden of chronic kidney disease in renal transplant recipients
    Karthikeyan, V
    Karpinski, J
    Nair, RC
    Knoll, G
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (02) : 262 - 269
  • [76] Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
    Kasiske, B
    Cosio, FG
    Beto, J
    Bolton, K
    Chavers, BM
    Grimm, R
    Levin, A
    Masri, B
    Parekh, R
    Wanner, C
    Wheeler, DC
    Wilson, PWF
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 13 - 53
  • [77] KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
    Kasiske, Bertram L.
    Zeier, Martin G.
    Chapman, Jeremy R.
    Craig, Jonathan C.
    Ekberg, Henrik
    Garvey, Catherine A.
    Green, Michael D.
    Jha, Vivekanand
    Josephson, Michelle A.
    Kiberd, Bryce A.
    Kreis, Henri A.
    McDonald, Ruth A.
    Newmann, John M.
    Obrador, Gregorio T.
    Vincenti, Flavio G.
    Cheung, Michael
    Earley, Amy
    Raman, Gowri
    Abariga, Samuel
    Wagner, Martin
    Balk, Ethan M.
    [J]. KIDNEY INTERNATIONAL, 2010, 77 (04) : 299 - 311
  • [78] Hypertension after kidney transplantation
    Kasiske, BL
    Anjum, S
    Shah, R
    Skogen, J
    Kandaswamy, C
    Danielson, B
    O'Shaughnessy, EA
    Dahl, DC
    Silkensen, JR
    Sahadevan, M
    Snyder, JJ
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (06) : 1071 - 1081
  • [79] Diabetes mellitus after kidney transplantation in the United States
    Kasiske, BL
    Snyder, JJ
    Gilbertson, D
    Matas, AJ
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (02) : 178 - 185
  • [80] Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis
    Knight, Simon R.
    Morris, Peter J.
    [J]. TRANSPLANTATION, 2010, 89 (01) : 1 - 14